Aktienanalyse zu Alcon AG (ALC)ALCAlcon AG

Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries. It operates in the Healthcare sector.

Currently, Alcon AG (ALC) is priced at $64.11, which is below the average analyst price target of $79.75, indicating potential upside. However, the stock has a high forward P/E ratio of 16.23, suggesting it may be overvalued relative to its earnings potential. The RSI is at 49.17, indicating a neutral momentum, and the stock has seen a year-to-date decline of 17.38%, which reflects ongoing challenges. The main risk is the recent drop in net income to zero in Q2 2026, which raises concerns about profitability moving forward.